Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Peter Kenemans

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Physiology

Postmenopause

Procedures

Chemicals & Drugs

Concepts & Ideas

Genes & Molecular Sequences

BRCA1 Genes

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
58
van der Mooren, Marius
48
Verheijen, René
28
van Kamp, Gerard
27
von Mensdorff-Pouilly, Silvia
23
van Diest, Paul
23
Hilgers, JH
22
Verstraeten, Rob
21
Mijatovic, Velja
19
Helmerhorst, Theo
19
van Baal, Marchien
18
Massuger, L F A G
17
Verstraeten, AA
16
Stehouwer, Coen
13
Menko, Fred
13
Bon, GG

Sign-in to see all Coauthors

Publications

TOP 3
Kenemans Peter; Bundred Nigel J; Foidart Jean-Michel; Kubista Ernst; von Schoultz Bo; Sismondi Piero; Vassilopoulou-Sellin Rena; Yip Cheng Har; Egberts Jan; Mol-Arts Mirjam; Mulder Roel; van Os Steve; Beckmann Matthias W;
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
Verbruggen Marjolijn B; van Diest Paul J; Baak Jan P; Broeckaert Mark A M; Kenemans Peter; Verheijen René H M
The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Kenemans (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kenemans Peter; Bundred Nigel J; Foidart Jean-Michel; Kubista Ernst; von Schoultz Bo; Sismondi Piero; Vassilopoulou-Sellin Rena; Yip Cheng Har; Egberts Jan; Mol-Arts Mirjam; Mulder Roel; van Os Steve; Beckmann Matthias W;
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
The lancet oncology 2009;10(2):135-46.
2009: de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
European journal of obstetrics, gynecology, and reproductive biology 2009;142(2):139-44.
2009: Verbruggen Marjolijn B; van Diest Paul J; Baak Jan P; Broeckaert Mark A M; Kenemans Peter; Verheijen René H M
The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2009;28(1):35-40.
2009: Verhoeven Marieke O; van der Mooren Marius J; Teerlink Tom; Verheijen René H M; Scheffer Peter G; Kenemans Peter
The influence of physiological and surgical menopause on coronary heart disease risk markers.
Menopause (New York, N.Y.) 2009;16(1):37-49.
2008: Kenemans P; Verstraeten R A; Verheijen R H M
Oncogenic pathways in hereditary and sporadic breast cancer.
Maturitas 2008;61(1-2):141-50.
2008: Ettinger Bruce; Kenemans Peter; Johnson Susan R; Mol-Arts Mirjam; Van Os Steve; Seifert Wilfried; Verweij Pierre J M; Cummings Steven R
Endometrial effects of tibolone in elderly, osteoporotic women.
Obstetrics and gynecology 2008;112(3):653-9.
2008: Hemelaar Majoie; van der Mooren Marius J; Rad Mandana; Kluft Cornelis; Kenemans Peter
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.
Fertility and sterility 2008;90(3):642-72.
2008: Cummings Steven R; Ettinger Bruce; Delmas Pierre D; Kenemans Peter; Stathopoulos Victoria; Verweij Pierre; Mol-Arts Mirjam; Kloosterboer Lenus; Mosca Lori; Christiansen Claus; Bilezikian John; Kerzberg Eduardo Mario; Johnson Susan; Zanchetta Jose; Grobbee Diederich E; Seifert Wilfried; Eastell Richard;
The effects of tibolone in older postmenopausal women.
The New England journal of medicine 2008;359(7):697-708.
2008: Bitzer Johannes; Kenemans Peter; Mueck Alfred O;
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.
Maturitas 2008;59(3):209-18.
2008: Hemelaar Majoie; Kenemans Peter; Hack C Erik; Klipping Christine; van der Mooren Marius J
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Menopause (New York, N.Y.) 2008;15(2):248-55.
2008: Davelaar Elvira M; van de Lande Jonas; von Mensdorff-Pouilly Silvia; Blankenstein Marinus A; Verheijen René H M; Kenemans Peter
A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008;29(1):9-17.
2007: Moreno María; Bontkes Hetty J; Scheper Rik J; Kenemans Peter; Verheijen René H M; von Mensdorff-Pouilly Silvia
High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).
Cancer letters 2007;257(1):47-55.
2007: Piek Jurgen M J; Kenemans Peter; Zweemer Ronald P; van Diest Paul J; Verheijen René H
Ovarian carcinogenesis, an alternative theory.
Gynecologic oncology 2007;107(2):355.
2007: Verhoeven Marieke O; Hemelaar Majoie; Teerlink Tom; Kenemans Peter; van der Mooren Marius J
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
Atherosclerosis 2007;195(1):181-8.
2007: Hermsen B B J; Verheijen R H M; Menko F H; Gille J J P; van Uffelen K; Blankenstein M A; Meijer S; van Diest P J; Kenemans P; von Mensdorff-Pouilly S
Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
European journal of cancer (Oxford, England : 1990) 2007;43(10):1556-63.
2007: Verhoeven Marieke O; Teerlink Tom; Kenemans Peter; Zuijdgeest-van Leeuwen Sonja D; van der Mooren Marius J
Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women.
Fertility and sterility 2007;87(4):849-57.
2007: Hermsen Brenda B J; von Mensdorff-Pouilly Silvia; Berkhof Johannes; van Diest Paul J; Gille Johan J P; Menko Fred H; Blankenstein Marinus A; Kenemans Peter; Verheijen René H M
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(11):1383-9.
2007: Verhoeven Marieke O; Teerlink Tom; Kenemans Peter; Vogelvang Tatjana E; van der Mooren Marius J;
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Menopause (New York, N.Y.) 2007;14(2):235-42.
2006: Piek Jurgen M J; Dorsman Josephine C; Massuger Leon F; Ansink Anca C; Weegenaar Jitske; Shvarts Avi; Kenemans Peter; Verheijen René H M
BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Archives of gynecology and obstetrics 2006;274(6):327-31.
2006: Hermsen Brenda B J; van Diest Paul J; Berkhof Johannes; Menko Fred H; Gille Johan J P; Piek Jurgen M J; Meijer Sybren; Winters Henri A H; Kenemans Peter; Mensdorff-Pouilly Silvia von; Verheijen René H M
Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
International journal of cancer. Journal international du cancer 2006;119(6):1412-8.
2006: Hemelaar Majoie; Rosing Jan; Kenemans Peter; Thomassen M Christella L G D; Braat Didi D M; van der Mooren Marius J
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(7):1660-6.
2006: Hemelaar M; Kenemans P; Schalkwijk C G; Braat D D M; van der Mooren M J
No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
Human reproduction (Oxford, England) 2006;21(6):1635-42.
2006: Hemelaar Majoie; Kenemans Peter; de Bie Lut; van de Weijer Peter H M; van der Mooren Marius J
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
Fertility and sterility 2006;85(4):979-88.
2006: Verhoeven M O; Hemelaar M; van der Mooren M J; Kenemans P; Teerlink T
Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
Journal of internal medicine 2006;259(2):199-208.
2006: Vogelvang Tatjana Elène; van der Mooren Marius Jan; Mijatovic Velja; Kenemans Peter
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Drugs 2006;66(2):191-221.
2005: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Emeis Jef J; Heijst Johannes A; van der Mooren Marius J
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
American journal of obstetrics and gynecology 2005;193(4):1384-94.
2005: Hemelaar Majoie; van der Mooren Marius J; van Baal W Marchien; Schalkwijk Casper G; Kenemans Peter; Stehouwer Coen D A
Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.
Menopause (New York, N.Y.) 2005;12(5):526-35.
2005: Verhoeven Marieke O; van der Mooren Marius J; van de Weijer Peter H M; Verdegem Peter J E; van der Burgt Leontine M J; Kenemans Peter;
Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study.
Menopause (New York, N.Y.) 2005;12(4):412-20.
2005: Hermsen Brenda B J; von Mensdorff-Pouilly Silvia; Fabry Hans F J; Winters Hay A H; Kenemans Peter; Verheijen René H M; van Diest Paul J
Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer.
The Journal of pathology 2005;206(2):220-3.
2005: Kenemans Peter
Postmenopausal hormone therapy and breast cancer: what is the problem?
Maturitas 2005;51(1):75-82.
2005: Kenemans P; Speroff L;
Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Maturitas 2005;51(1):21-8.
2005: Korstjens Iolente J M; Smolders Raimond G V; van der Mooren Marius J; Kloosterboer Helenius J; Kenemans Peter; Sipkema Pieter
Endothelium-dependent dilatory effects of 3alpha-OH-tibolone in gracilis muscle arterioles of the female Wistar rat.
Menopause (New York, N.Y.) 2005;12(3):340-7.
2005: Smolders R G V; de Meer K; Kenemans P; Jakobs C; Kulik W; van der Mooren M J
Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.
The Journal of clinical endocrinology and metabolism 2005;90(4):2218-24.
2005: Post Marinka S; Leurs Judith R; van der Mooren Marius J; van Baal W Marchien; Hendriks Dirk F; Stehouwer Coen D A; Kenemans Peter
Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study.
Thrombosis and haemostasis 2005;93(3):620-2.
2004: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Teerlink Tom; van der Mooren Marius J
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.
Fertility and sterility 2004;82(6):1540-9.
2004: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Schalkwijk Casper G; van der Mooren Marius J
Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
The American journal of cardiology 2004;94(9):1205-8.
2004: de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
Maturitas 2004;49(3):253-63.
2004: Smolders R G V; de Meer K; Kenemans P; Teerlink T; Jakobs C; van der Mooren M J
Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.
European journal of obstetrics, gynecology, and reproductive biology 2004;117(1):55-9.
2004: Pijpers Rik; Buist Marrije R; van Lingen Arthur; Dijkstra Jan; van Diest Paul J; Teule Gerrit J J; Kenemans Peter; Verheijen René H M
The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy.
European journal of nuclear medicine and molecular imaging 2004;31(11):1479-86.
2004: Piek Jurgen M J; Kenemans Peter; Verheijen René H M
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.
American journal of obstetrics and gynecology 2004;191(3):718-32.
2004: Kenemans P; Verstraeten R A; Verheijen R H M
Oncogenic pathways in hereditary and sporadic breast cancer.
Maturitas 2004;49(1):34-43.
2004: Kenemans P; Genazzani A R; Palacios S; Schneider H P G
Pulsed estrogen exposure selectively modulates tissue response: a hypothesis.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2004;18(3):159-64.
2004: van der Mooren M J; Kenemans P
The Million Women Study: a licence to kill other investigations?
European journal of obstetrics, gynecology, and reproductive biology 2004;113(1):3-5.
2004: Piek Jurgen M J; Dorsman Josephine C; Shvarts Avi; Ansink Anca C; Massuger Leon F A G; Scholten Piet; van Diest Paul J; Dijkstra Jan C; Weegenaar Jitske; Kenemans Peter; Verheijen René H M
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma.
Gynecologic oncology 2004;92(3):819-26.
2004: Vogelvang Tatjana E; Leurs Judith R; van der Mooren Marius J; Mijatovic Velja; Hendriks Dirk F; Neele Simone J M; Netelenbos J Coen; Kenemans Peter
Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
Menopause (New York, N.Y.) 2004;11(1):110-5.
2004: Smolders Raimond G V; Sipkema Pieter; Kenemans Peter; Stehouwer Coen D A; Van Der Mooren Marius J
Homocysteine impairs estrogen-induced vasodilation in isolated rat arterioles.
Menopause (New York, N.Y.) 2004;11(1):98-103.
2004: van der Mooren Marius Jan; Kenemans Peter
Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.
Drugs 2004;64(8):821-36.
2003: Post Marinka S; van der Mooren Marius J; van Baal W Marchien; Blankenstein Marinus A; Merkus Hans M W M; Kroeks Maurice V A M; Franke Henk R; Kenemans Peter; Stehouwer Coen D A
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
American journal of obstetrics and gynecology 2003;189(5):1221-7.
2003: Davelaar Elvira M; Schutter Eltjo M J; von Mensdorff-Pouilly Silvia; van Kamp Gerard J; Verstraeten Rob A; Kenemans Peter
Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Annals of clinical biochemistry 2003;40(Pt 6):663-73.
2003: Hemelaar Majoie; van der Mooren Marius J; Mijatovic Velja; Bouman Anneke A; Schijf Charles P T; Kroeks Maurice V A M; Franke Henk R; Kenemans Peter
Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
Menopause (New York, N.Y.) 2003;10(6):550-8.
2003: Post Marinka S; Verhoeven Marieke O; van der Mooren Marius J; Kenemans Peter; Stehouwer Coen D A; Teerlink Tom
Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
The Journal of clinical endocrinology and metabolism 2003;88(9):4221-6.
2003: Vogelvang Tatjana E; van der Mooren Marius J; Kamp Otto; Mijatovic Velja; Visser Cees A; Kenemans Peter
Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function.
Fertility and sterility 2003;80(3):546-53.
2003: Smolders R G V; van der Mooren M J; Sipkema P; Kenemans P
Estrogens, homocysteine, vasodilatation and menopause: basic mechanisms, interactions and clinical implications.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2003;17(4):339-54.
2003: Piek Jurgen M J; Verheijen René H M; Kenemans Peter; Massuger Leon F; Bulten Hans; van Diest Paul J
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis.
Gynecologic oncology 2003;90(2):491.
2003: Buist Marrije R; Pijpers Rik J; van Lingen Arthur; van Diest Paul J; Dijkstra Jan; Kenemans Peter; Verheijen René H M
Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer.
Gynecologic oncology 2003;90(2):290-6.
2003: Piek J M J; Verheijen R H M; Menko F H; Jongsma A P M; Weegenaar J; Gille J J P; Pals G; Kenemans P; van Diest P J
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition.
Histopathology 2003;43(1):26-32.
2003: Post Marinka S; Christella M; Thomassen L G D; van der Mooren Marius J; van Baal W Marchien; Rosing Jan; Kenemans Peter; Stehouwer Coen D A
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(6):1116-21.
2003: Kenemans P; Bosman A
Breast cancer and post-menopausal hormone therapy.
Best practice & research. Clinical endocrinology & metabolism 2003;17(1):123-37.
2003: Smolders R G V; van der Mooren M J; Teerlink T; Merkus J M W M; Kroeks M V A M; Franke H R; Stehouwer C D A; Kenemans P
A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.
Fertility and sterility 2003;79(2):261-7.
2003: Piek Jurgen M J; Torrenga Bas; Hermsen Brenda; Verheijen René H M; Zweemer Ronald P; Gille Johan J P; Kenemans Peter; van Diest Paul J; Menko Fred H
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Familial cancer 2003;2(2):73-8.
2002: Post Marinka S; Rosing Jan; Van Der Mooren Marius J; Zweegman Sonja; Van Baal W Marchien; Kenemans Peter; Stehouwer Coen D A;
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
British journal of haematology 2002;119(4):1017-23.
2002: Post M S; van der Mooren M J; Stehouwer C D A; van Baal W M; Mijatovic V; Schalkwijk C G; Kenemans P
Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial.
Thrombosis and haemostasis 2002;88(4):605-10.
2002: Jongsma A P M; Piek J M J; Zweemer R P; Verheijen R H M; Klein Gebbinck J W T; van Kamp G J; Jacobs I J; Shaw P; van Diest P J; Kenemans P
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.
Molecular pathology : MP 2002;55(5):305-9.
2002: Shaw P A; McLaughlin J R; Zweemer R P; Narod S A; Risch H; Verheijen R H M; Ryan A; Menko F H; Kenemans P; Jacobs I J
Histopathologic features of genetically determined ovarian cancer.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2002;21(4):407-11.
2002: van Zanten-Przybysz Iwona; Molthoff Carla; Gebbinck Jacqueline Klein; von Mensdorff-Pouilly Silvia; Verstraeten Rob; Kenemans Peter; Verheijen René
Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study.
Journal of cancer research and clinical oncology 2002;128(9):484-92.
2002: Schutter Eltjo M J; Davelaar Elvira M; van Kamp Gerard J; Verstraeten Rob A; Kenemans Peter; Verheijen René H M
The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
American journal of obstetrics and gynecology 2002;187(2):385-92.
2002: Smolders Ramon G V; van der Mooren Marius J; Kenemans Peter; van der Linden Peter W J; Stehouwer Coen D A; Sipkema Pieter
17 beta-Estradiol induces a rapid, endothelium-dependent, sex-specific vasodilatation in spontaneous constricted rat arterioles.
American journal of obstetrics and gynecology 2002;187(2):375-81.
2002: Thijs A; van Baal W M; van der Mooren M J; Kenemans P; Dräger A M; Huijgens P C; Stehouwer C D A
Effects of hormone replacement therapy on blood platelets.
European journal of clinical investigation 2002;32(8):613-8.
2002: Vogelvang Tatjana E; Mijatovic Velja; Kamp Otto; Netelenbos J Coen; Neele Simone J M; Pines Amos; Kenemans Peter; van der Mooren Marius J
Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
American journal of obstetrics and gynecology 2002;186(4):729-36.
2002: Post M S; Hendriks D F; Van Der Mooren M J; Van Baal W M; Leurs J R; Emeis J J; Kenemans P; Stehouwer C D A
Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
Journal of internal medicine 2002;251(3):245-51.
2002: Smolders Raimond G V; Vogelvang Tatjana E; Mijatovic Velja; van Baal W Marchien; Neele Simone J M; Netelenbos J Coen; Kenemans Peter; van der Mooren Marius J
A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
Maturitas 2002;41(2):105-14.
2001: Piek J M; van Diest P J; Zweemer R P; Jansen J W; Poort-Keesom R J; Menko F H; Gille J J; Jongsma A P; Pals G; Kenemans P; Verheijen R H
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
The Journal of pathology 2001;195(4):451-6.
2001: Zweemer R P; Ryan A; Snijders A M; Hermsen M A; Meijer G A; Beller U; Menko F H; Jacobs I J; Baak J P; Verheijen R H; Kenemans P; van Diest P J
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma.
Laboratory investigation; a journal of technical methods and pathology 2001;81(10):1363-70.
2001: Zweemer R P; Verheijen R H; Coebergh J W; Jacobs I J; van Diest P J; Gille J J; Skates S; Menko F H; Ten Kate L P; Kenemans P
Survival analysis in familial ovarian cancer, a case control study.
European journal of obstetrics, gynecology, and reproductive biology 2001;98(2):219-23.
2001: Piek J M; van Diest P J; Zweemer R P; Kenemans P; Verheijen R H
Tubal ligation and risk of ovarian cancer.
Lancet 2001;358(9284):844.
2001: Post M S; van der Mooren M J; van Baal W M; Neele S J; Netelenbos J C; Kenemans P
Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.
American journal of obstetrics and gynecology 2001;185(3):557-62.
2001: Snijdewint F G; von Mensdorff-Pouilly S; Karuntu-Wanamarta A H; Verstraeten A A; Livingston P O; Hilgers J; Kenemans P
Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
International journal of cancer. Journal international du cancer 2001;93(1):97-106.
2001: Kenemans P; van Unnik G A; Mijatovic V; van der Mooren M J
Perspectives in hormone replacement therapy.
Maturitas 2001;38 Suppl 1():S41-8.
2001: Piek J M; van Diest P J; Verheijen R H; Kenemans P
Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tube.
Histopathology 2001;38(5):481-2.
2001: Bon G G; Kenemans P; Verstraeten A A; Go S; Philipi P A; van Kamp G J; van Geijn H P; van Vugt J M
Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy.
Fetal diagnosis and therapy 2001;16(3):166-72.
2001: Kessel H; Kamp O; Kenemans P; Mijatovic V; van Baal W M; Visser C A; van der Mooren M J
Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.
American journal of obstetrics and gynecology 2001;184(5):910-6.
2001: van Zanten-Przybysz I; Molthoff C F; Roos J C; Verheijen R H; van Hof A; Buist M R; Prinssen H M; den Hollander W; Kenemans P
Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.
International journal of cancer. Journal international du cancer 2001;92(1):106-14.
2001: Nijman H W; van Diest P J; Poort-Keesom R J; von Mensdorff-Pouilly S; Verstraeten R A; Kummer A; Meijer C J; Melief C J; Hilgers J; Kenemans P
T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
European journal of obstetrics, gynecology, and reproductive biology 2001;94(1):114-20.
2000: von Mensdorff-Pouilly S; Snijdewint F G; Verstraeten A A; Verheijen R H; Kenemans P
Human MUC1 mucin: a multifaceted glycoprotein.
The International journal of biological markers 2000;15(4):343-56.
2000: Neele S J; Marchien van Baal W; van der Mooren M J; Kessel H; Netelenbos J C; Kenemans P
Ultrasound assessment of the endometrium in healthy, asymptomatic early post-menopausal women: saline infusion sonohysterography versus transvaginal ultrasound.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2000;16(3):254-9.
2000: Verheijen R H; Pijpers R; van Diest P J; Burger C W; Buist M R; Kenemans P
Sentinel node detection in cervical cancer.
Obstetrics and gynecology 2000;96(1):135-8.
2000: van Zanten-Przybysz I; Molthoff C F; Roos J C; Plaizier M A; Visser G W; Pijpers R; Kenemans P; Verheijen R H
Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(7):1168-76.
2000: Ryuko K; Schol D J; Snijdewint F G; von Mensdorff-Pouilly S; Poort-Keesom R J; Karuntu-Wanamarta Y A; Verstraeten R A; Miyazaki K; Kenemans P; Hilgers J
Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2000;21(4):197-210.
2000: von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten A A; Snijdewint F G; van Kamp G J; Schol D J; Reis C A; Price M R; Livingston P O; Hilgers J
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
International journal of cancer. Journal international du cancer 2000;86(5):702-12.
2000: Hopman E H; Rozendaal L; Voorhorst F J; Walboomers J M; Kenemans P; Helmerhorst T J
High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy.
BJOG : an international journal of obstetrics and gynaecology 2000;107(5):600-4.
2000: Klip H; Burger C W; Kenemans P; van Leeuwen F E
Cancer risk associated with subfertility and ovulation induction: a review.
Cancer causes & control : CCC 2000;11(4):319-44.
2000: von Mensdorff-Pouilly S; Verstraeten A A; Kenemans P; Snijdewint F G; Kok A; Van Kamp G J; Paul M A; Van Diest P J; Meijer S; Hilgers J
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):574-83.
2000: van Baal W M; Emeis J J; van der Mooren M J; Kessel H; Kenemans P; Stehouwer C D
Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
Thrombosis and haemostasis 2000;83(1):29-34.
2000: Zweemer R P; van Diest P J; Verheijen R H; Ryan A; Gille J J; Sijmons R H; Jacobs I J; Menko F H; Kenemans P
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
Gynecologic oncology 2000;76(1):45-50.
1999: Scheele F; Burger C W; Kenemans P
Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer.
Maturitas 1999;33(3):191-6.
1999: van Baal W M; Kenemans P; Stehouwer C D; Peters-Muller E R; van Vugt J M; van der Mooren M J
Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women.
American journal of obstetrics and gynecology 1999;181(6):1365-73.
1999: de Valk-de Roo G W; Stehouwer C D; Meijer P; Mijatovic V; Kluft C; Kenemans P; Cohen F; Watts S; Netelenbos C
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.
Arteriosclerosis, thrombosis, and vascular biology 1999;19(12):2993-3000.
1999: Van Baal W M; Emeis J J; Kenemans P; Kessel H; Peters-Muller E R; Schalkwijk C G; van der Mooren M J; Stehouwer C D
Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules.
European journal of clinical investigation 1999;29(11):913-21.
1999: van Baal W M; Smolders R G; van der Mooren M J; Teerlink T; Kenemans P
Hormone replacement therapy and plasma homocysteine levels.
Obstetrics and gynecology 1999;94(4):485-91.
1999: Nobbenhuis M A; Walboomers J M; Helmerhorst T J; Rozendaal L; Remmink A J; Risse E K; van der Linden H C; Voorhorst F J; Kenemans P; Meijer C J
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.
Lancet 1999;354(9172):20-5.
1999: van de Weijer P H; Scholten P C; van der Mooren M J; Barentsen R; Kenemans P
Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
Climacteric : the journal of the International Menopause Society 1999;2(2):101-9.
1999: Burger C W; van Leeuwen F E; Scheele F; Kenemans P
Hormone replacement therapy in women treated for gynaecological malignancy.
Maturitas 1999;32(2):69-76.
1999: van Baal W M; Kenemans P; van der Mooren M J; Kessel H; Emeis J J; Stehouwer C D
Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
Thrombosis and haemostasis 1999;81(6):925-8.
1999: Zweemer R P; Shaw P A; Verheijen R M; Ryan A; Berchuck A; Ponder B A; Risch H; McLaughlin J R; Narod S A; Menko F H; Kenemans P; Jacobs I J
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Journal of clinical pathology 1999;52(5):372-5.
1999: Mijatovic V; van der Mooren M J; Stehouwer C D; Netelenbos J C; Kenemans P
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1999;13(2):130-44.
1999: Nijman H W; Kenemans P; Poort-Keesom R J; Verstraeten R A; Mensdorff-Pouilly S; Verheijen R H; Melief C J; Hilgers J; Meijer C J
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
European journal of obstetrics, gynecology, and reproductive biology 1999;83(2):201-6.
1999: Snijdewint F G; von Mensdorff-Pouilly S; Karuntu-Wanamarta A H; Verstraeten A A; van Zanten-Przybysz I; Hummel P; Nijman H W; Kenemans P; Hilgers J
Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Cancer immunology, immunotherapy : CII 1999;48(1):47-55.
1999: van de Weijer P H; Barentsen R; de Vries M; Kenemans P
Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy.
Obstetrics and gynecology 1999;93(4):551-7.
1999: van Baal W M; Kenemans P; Emeis J J; Schalkwijk C G; Mijatovic V; van der Mooren M J; Vischer U M; Stehouwer C D
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.
Fertility and sterility 1999;71(4):663-70.
1999: Verheijen R H; von Mensdorff-Pouilly S; van Kamp G J; Kenemans P
CA 125: fundamental and clinical aspects.
Seminars in cancer biology 1999;9(2):117-24.
1999: Bon G G; van Kamp G J; Verstraeten R A; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Quantification of MUC1 in breast cancer patients. A method comparison study.
European journal of obstetrics, gynecology, and reproductive biology 1999;83(1):67-75.
1999: Zweemer R P; Verheijen R H; Menko F H; Gille J J; van Diest P J; Coebergh J W; Shaw P A; Jacobs I J; Kenemans P
Differences between hereditary and sporadic ovarian cancer.
European journal of obstetrics, gynecology, and reproductive biology 1999;82(2):151-3.
1999: Bon G G; Kenemans P; Dekker J J; Hompes P G; Verstraeten R A; van Kamp G J; Schoemaker J
Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles.
Human reproduction (Oxford, England) 1999;14(2):566-70.
1999: Davies Q; Perkins A C; Roos J C; Molthoff C F; Verheijen R H; Frier M; Kenemans P; Broadhead T; Sopwith M; Symonds E M
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma.
British journal of obstetrics and gynaecology 1999;106(1):31-7.
1999: Kok A L; Burger C W; van de Weijer P H; Voetberg G A; Peters-Muller E R; Kenemans P
Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study.
Maturitas 1999;31(2):143-9.
1999: Mijatovic V; van der Mooren M J; Kenemans P; de Valk-de Roo G W; Netelenbos C
Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Menopause (New York, N.Y.) 1999;6(2):134-7.
1998: Mijatovic V; Netelenbos C; van der Mooren M J; de Valk-de Roo G W; Jakobs C; Kenemans P
Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
Fertility and sterility 1998;70(6):1085-9.
1998: van de Weijer P H; Barentsen R; Kenemans P
Women's expectations and acceptance of cyclic induced HRT bleeds.
Maturitas 1998;30(3):257-63.
1998: van Ittersum F J; van Baal W M; Kenemans P; Mijatovic V; Donker A J; van der Mooren M J; Stehouwer C D
Ambulatory--not office--blood pressures decline during hormone replacement therapy in healthy postmenopausal women.
American journal of hypertension 1998;11(10):1147-52.
1998: Prinssen H M; Molthoff C F; Verheijen R H; Broadhead T J; Kenemans P; Roos J C; Davies Q; van Hof A C; Frier M; den Hollander W; Wilhelm A J; Baker T S; Sopwith M; Symonds E M; Perkins A C
Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01.
Cancer immunology, immunotherapy : CII 1998;47(1):39-46.
1998: Davelaar E M; van Kamp G J; Verstraeten R A; Kenemans P
Comparison of seven immunoassays for the quantification of CA 125 antigen in serum.
Clinical chemistry 1998;44(7):1417-22.
1998: Mijatovic V; Kenemans P; Netelenbos C; Jakobs C; Popp-Snijders C; Peters-Muller E R; van der Mooren M J
Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Fertility and sterility 1998;69(5):876-82.
1998: Hopman E H; Rozendaal L; Verheijen R H; Kenemans P; Helmerhorst T J
Digital color imaging colposcopy: a matter of choice.
European journal of obstetrics, gynecology, and reproductive biology 1998;77(2):229-34.
1998: Schutter E M; Sohn C; Kristen P; Möbus V; Crombach G; Kaufmann M; Caffier H; Kreienberg R; Verstraeten A A; Kenemans P
Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.
Gynecologic oncology 1998;69(1):56-63.
1998: Mijatovic V; Kenemans P; Jakobs C; van Baal W M; Peters-Muller E R; van der Mooren M J
A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.
Obstetrics and gynecology 1998;91(3):432-6.
1998: Hopman E H; Kenemans P; Helmerhorst T J
Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature.
Obstetrical & gynecological survey 1998;53(2):97-106.
1998: von Mensdorff-Pouilly S; Gourevitch M M; Kenemans P; Verstraeten A A; van Kamp G J; Kok A; van Uffelen K; Snijdewint F G; Paul M A; Meijer S; Hilgers J
An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19(3):186-95.
1998: Schol D J; Meulenbroek M F; Snijdewint F G; von Mensdorff-Pouilly S; Verstraeten R A; Murakami F; Kenemans P; Hilgers J
'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19 Suppl 1():35-45.
1998: Price M R; Rye P D; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek M F; Snijdewint F G; von Mensdorff-Pouilly S; Verstraeten R A; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh M R; Koganty R R; Fortier S; Baronic L; Berg A; Longenecker M B; Hilgers J
Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1998;19 Suppl 1():1-20.
1997: de Valk-de Roo G W; Netelenbos J C; Peters-Muller I R; Voetberg G A; van de Weijer P H; Bouman A A; Popp-Snijders C; Kenemans P
Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.
Maturitas 1997;28(2):153-62.
1997: Molthoff C F; Prinssen H M; Kenemans P; van Hof A C; den Hollander W; Verheijen R H
Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study.
Cancer 1997;80(12 Suppl):2712-20.
1997: Mijatovic V; Kenemans P; Netelenbos J C; Peters-Muller E R; van Kamp G J; Voetberg G A; van de Weijer P H; van der Mooren M J
Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
The Journal of clinical endocrinology and metabolism 1997;82(11):3543-7.
1997: Veenhuizen R B; Ruevekamp M C; Oppelaar H; Helmerhorst T J; Kenemans P; Stewart F A
Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies.
International journal of cancer. Journal international du cancer 1997;73(2):230-5.
1997: Veenhuizen R B; Ruevekamp M C; Oppelaar H; Ransdorp B; van de Vijver M; Helmerhorst T J; Kenemans P; Stewart F A
Intraperitoneal photodynamic therapy: comparison of red and green light distribution and toxicity.
Photochemistry and photobiology 1997;66(3):389-95.
1997: Gaarenstroom K N; Bonfrer J M; Korse C M; Kenter G G; Kenemans P
Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Anticancer research 1997;17(4B):2955-8.
1997: Vennegoor C J; Nijman H W; Drijfhout J W; Vernie L; Verstraeten R A; von Mensdorff-Pouilly S; Hilgers J; Verheijen R H; Kast W M; Melief C J; Kenemans P
Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.
Cancer letters 1997;116(1):93-101.
1997: Bonfrer J M; Gaarenstroom K N; Korse C M; Van Bunningen B N; Kenemans P
Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Anticancer research 1997;17(3C):2329-34.
1997: Bon G G; von Mensdorff-Pouilly S; Kenemans P; van Kamp G J; Verstraeten R A; Hilgers J; Meijer S; Vermorken J B
Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays.
Clinical chemistry 1997;43(4):585-93.
1997: Schutter E M; Mulder C; van Kamp G J; Kenemans P
The beta-core fragment of human chorionic gonadotropin: biochemical background and clinical application.
Anticancer research 1997;17(2B):1255-72.
1997: Bonfrer J M; Korse C M; Verstraeten R A; van Kamp G J; Hart G A; Kenemans P
Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
Clinical chemistry 1997;43(3):491-7.
1997: Burger C W; Koomen I; Peters N A; van Leeuwen F E; Kenemans P
[Postmenopausal hormone replacement therapy and cancer of the female genitalia and breast]
Nederlands tijdschrift voor geneeskunde 1997;141(8):368-72.
1997: Kenemans P; Scheele F; Burger C W
Hormone replacement therapy and breast cancer morbidity, mortality and recurrence.
European journal of obstetrics, gynecology, and reproductive biology 1997;71(2):199-203.
1997: Pines A; Mijatovic V; van der Mooren M J; Kenemans P
Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations.
European journal of obstetrics, gynecology, and reproductive biology 1997;71(2):193-7.
1996: Rozendaal L; Walboomers J M; van der Linden J C; Voorhorst F J; Kenemans P; Helmerhorst T J; van Ballegooijen M; Meijer C J
PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.
International journal of cancer. Journal international du cancer 1996;68(6):766-9.
1996: van Hof A C; Molthoff C F; Davies Q; Perkins A C; Verheijen R H; Kenemans P; den Hollander W; Wilhelm A J; Baker T S; Sopwith M; Frier M; Symonds E M; Roos J C
Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.
Cancer research 1996;56(22):5179-85.
1996: von Mensdorff-Pouilly S; Gourevitch M M; Kenemans P; Verstraeten A A; Litvinov S V; van Kamp G J; Meijer S; Vermorken J; Hilgers J
Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1325-31.
1996: Burger C W; Prinssen H M; Kenemans P
LHRH agonist treatment of breast cancer and gynecological malignancies: a review.
European journal of obstetrics, gynecology, and reproductive biology 1996;67(1):27-33.
1996: Davelaar E M; Bonfrer J M; Verstraeten R A; ten Bokkel Huinink W W; Kenemans P
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?
Cancer 1996;78(1):118-27.
1996: Veenhuizen R B; Marijnissen J P; Kenemans P; Ruevekamp-Helmers M C; 't Mannetje L W; Helmerhorst T J; Stewart F A
Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma.
British journal of cancer 1996;73(11):1387-92.
1996: Boerrigter P J; van de Weijer P H; Baak J P; Fox H; Haspels A A; Kenemans P
Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.
Maturitas 1996;24(1-2):63-71.
1996: Bon G G; Kenemans P; Verstraeten R; van Kamp G J; Hilgers J
Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
American journal of obstetrics and gynecology 1996;174(1 Pt 1):107-14.
1996: van Kamp G J; Bon G G; Verstraeten R A; Lynch D; Krikau M; Flückiger J; Ruibal A; Kenemans P
Multicenter evaluation of the Abbott IMx CA 15-3 assay.
Clinical chemistry 1996;42(1):28-33.
1996: Bon G G; Verheijen R H; Zuetenhorst J M; van Kamp G J; Verstraeten A A; Kenemans P
Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
Gynecologic and obstetric investigation 1996;42(1):58-62.
1995: Gourevitch M M; von Mensdorff-Pouilly S; Litvinov S V; Kenemans P; van Kamp G J; Verstraeten A A; Hilgers J
Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.
British journal of cancer 1995;72(4):934-8.
1995: Hopman E H; Voorhorst F J; Kenemans P; Meyer C J; Helmerhorst T J
Observer agreement on interpreting colposcopic images of CIN.
Gynecologic oncology 1995;58(2):206-9.
1995: Nijman H W; Kleijmeer M J; Ossevoort M A; Oorschot V M; Vierboom M P; van de Keur M; Kenemans P; Kast W M; Geuze H J; Melief C J
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells.
The Journal of experimental medicine 1995;182(1):163-74.
1995: Buist M R; Molthoff C F; Kenemans P; Meijer C J
Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.
Journal of clinical pathology 1995;48(7):631-6.
1995: Remmink A J; Walboomers J M; Helmerhorst T J; Voorhorst F J; Rozendaal L; Risse E K; Meijer C J; Kenemans P
The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.
International journal of cancer. Journal international du cancer 1995;61(3):306-11.
1995: Buist M R; Kenemans P; Molthoff C F; Roos J C; Den Hollander W; Brinkhuis M; Baak J P
Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics.
International journal of cancer. Journal international du cancer 1995;64(2):92-8.
1995: Kenemans P; Verstraeten A A; van Kamp G J; von Mensdorff-Pouilly S
The second generation CA 125 assays.
Annals of medicine 1995;27(1):107-13.
1995: Buist M R; Kenemans P; van Kamp G J; Haisma H J
Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
Cancer immunology, immunotherapy : CII 1995;40(1):24-30.
1995: Hilgers J; von Mensdorff-Pouilly S; Verstraeten A A; Kenemans P
Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists.
Scandinavian journal of clinical and laboratory investigation. Supplementum 1995;221():81-6.
1994: Veenhuizen R B; Ruevekamp-Helmers M C; Helmerhorst T J; Kenemans P; Mooi W J; Marijnissen J P; Stewart F A
Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC.
International journal of cancer. Journal international du cancer 1994;59(6):830-6.
1994: Bonfrer J M; Gaarenstroom K N; Kenter G G; Korse C M; Hart A A; Gallee M P; Helmerhorst T J; Kenemans P
Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer.
Gynecologic oncology 1994;55(3 Pt 1):371-5.
1994: Voetberg G A; Netelenbos J C; Kenemans P; Peters-Muller E R; van de Weijer P H
Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.
The Journal of clinical endocrinology and metabolism 1994;79(5):1465-9.
1994: van Bommel P F; Kenemans P; Helmerhorst T J; Gallee M P; Ivanyi D
Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix.
Cancer 1994;74(8):2314-20.
1994: Schutter E M; Kenemans P; Sohn C; Kristen P; Crombach G; Westermann R; Môbus V; Kaufmann M; Caffier H; Schmidt-Rhode P
Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study.
Cancer 1994;74(4):1398-406.
1994: Cromme F V; van Bommel P F; Walboomers J M; Gallee M P; Stern P L; Kenemans P; Helmerhorst T J; Stukart M J; Meijer C J
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.
British journal of cancer 1994;69(6):1176-81.
1994: Bonfrer J M; Baan A W; Jansen E; Lentfer D; Kenemans P
Technical evaluation of three second generation CA 125 assays.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1994;32(3):201-7.
1994: Buist M R; Golding R P; Burger C W; Vermorken J B; Kenemans P; Schutter E M; Baak J P; Heitbrink M A; Falke T H
Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI.
Gynecologic oncology 1994;52(2):191-8.
1994: Verheijen R H; Menko F H; Kenemans P
[Familial ovarian carcinoma]
Nederlands tijdschrift voor geneeskunde 1994;138(2):63-6.
1993: Kenemans P; van Kamp G J; Oehr P; Verstraeten R A
Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum.
Clinical chemistry 1993;39(12):2509-13.
1993: Cromme F V; Snijders P J; van den Brule A J; Kenemans P; Meijer C J; Walboomers J M
MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression.
Oncogene 1993;8(11):2969-75.
1993: Buist M R; Kenemans P; den Hollander W; Vermorken J B; Molthoff C J; Burger C W; Helmerhorst T J; Baak J P; Roos J C
Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.
Cancer research 1993;53(22):5413-8.
1993: Houbiers J G; Nijman H W; van der Burg S H; Drijfhout J W; Kenemans P; van de Velde C J; Brand A; Momburg F; Kast W M; Melief C J
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
European journal of immunology 1993;23(9):2072-7.
1993: van Kasteren Y M; Burger C W; Meijer O W; Helmerhorst T J; Kenemans P
Efficacy of a synthetic mesh sling in keeping the small bowel in the upper abdomen to prevent radiation enteropathy in gynecologic malignancies.
European journal of obstetrics, gynecology, and reproductive biology 1993;50(3):211-8.
1993: Nijman H W; Houbiers J G; van der Burg S H; Vierboom M P; Kenemans P; Kast W M; Melief C J
Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):121-6.
1993: Yedema C A; Kenemans P; Voorhorst F; Bon G; Schijf C; Beex L; Verstraeten A; Hilgers J; Vermorken J
CA 125 half-life in ovarian cancer: a multivariate survival analysis.
British journal of cancer 1993;67(6):1361-7.
1993: van Kamp G J; von Mensdorff-Pouilly S; Kenemans P; Verstraeten R; Yedema C A; Wobbes T; Bon G G; Kok A; Brown J P; Hilgers J
Evaluation of colorectal cancer-associated mucin CA M43 assay in serum.
Clinical chemistry 1993;39(6):1029-32.
1993: Cromme F V; Meijer C J; Snijders P J; Uyterlinde A; Kenemans P; Helmerhorst T; Stern P L; van den Brule A J; Walboomers J M
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions.
British journal of cancer 1993;67(6):1372-80.
1993: Nijman H W; Houbiers J G; Vierboom M P; van der Burg S H; Drijfhout J W; D'Amaro J; Kenemans P; Melief C J; Kast W M
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.
European journal of immunology 1993;23(6):1215-9.
1993: van Kamp G J; Verstraeten A A; Kenemans P
Discordant serum CA 125 values in commercial immunoassays.
European journal of obstetrics, gynecology, and reproductive biology 1993;49(1-2):99-103.
1993: Kenemans P; Yedema C A; Bon G G; von Mensdorff-Pouilly S
CA 125 in gynecological pathology--a review.
European journal of obstetrics, gynecology, and reproductive biology 1993;49(1-2):115-24.
1993: van Bommel P F; van den Brule A J; Helmerhorst T J; Gallee M P; Gaarenstroom K N; Walboomers J M; Meijer C J; Kenemans P
HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer.
Gynecologic oncology 1993;48(3):333-7.
1993: Yedema K A; Verheijen R H; Kenemans P; Schijf C P; Borm G F; Segers M F; Thomas C M
Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve.
American journal of obstetrics and gynecology 1993;168(3 Pt 1):787-92.
1993: Richters C D; Burger C W; van de Loosdrecht A A; van Rijswijk R E; Calame W; Bleker O P; Vermorken J B; Kenemans P; Beelen R H
The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment.
Cancer letters 1993;68(1):25-31.
1993: Yedema C A; Kenemans P; Thomas C M; Massuger L F; Wobbes T; Verstraeten R; van Kamp G J; Hilgers J
CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery.
European journal of cancer (Oxford, England : 1990) 1993;29A(7):966-71.
1992: Tibben J G; Massuger L F; Claessens R A; Schijf C P; Pak K Y; Strijk S P; Kenemans P; Corstens F H
Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer.
Nuclear medicine communications 1992;13(12):885-93.
1992: Yedema K A; Thomas C M; Segers M F; Doesburg W H; Kenemans P
Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
European journal of obstetrics, gynecology, and reproductive biology 1992;47(3):245-52.
1992: Molthoff C F; Buist M R; Kenemans P; Pinedo H M; Boven E
Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(11):2000-5.
1992: Massuger L F; Thomas C M; Segers M F; Corstens F H; Verheijen R H; Kenemans P; Poels L G
Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(11):1958-63.
1992: Karsdorp V H; Van der Veen F; Schats R; Boer-Meisel M E; Kenemans P
Successful treatment with methotrexate of five vital interstitial pregnancies.
Human reproduction (Oxford, England) 1992;7(8):1164-9.
1992: Kenemans P; Bon G G; Kessler A C; Verstraeten A A; van Kamp G J
Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125.
Clinical chemistry 1992;38(8 Pt 1):1466-71.
1992: Melkert P W; Walboomers J M; Jiwa N M; Cuesta M A; Kenemans P; Meijer C J
Multiple HPV 16-related squamous cell carcinomas of the vulva, vagina, anus, skin and cervix in a 31-year-old woman.
European journal of obstetrics, gynecology, and reproductive biology 1992;46(1):53-6.
1992: Buijs W C; Massuger L F; Claessens R A; Kenemans P; Corstens F H
Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(6):1113-20.
1992: Kok A L; Voorhorst F J; Burger C W; van Houten P; Kenemans P; Janssens J
Urinary and faecal incontinence in community-residing elderly women.
Age and ageing 1992;21(3):211-5.
1992: Keijser K G; Kenemans P; van der Zanden P H; Schijf C P; Vooijs G P; Rolland R
Diathermy loop excision in the management of cervical intraepithelial neoplasia: diagnosis and treatment in one procedure.
American journal of obstetrics and gynecology 1992;166(4):1281-7.
1992: Schutter E M; Visser J J; van Kamp G J; Mensdorff-Pouilly S; van Dijk W; Hilgers J; Kenemans P
The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992;13(3):121-32.
1992: Yedema C A; Kenemans P; Wobbes T; Thomas C M; Bon G G; Mulder C; Voorhorst F J; Verstraeten A A; van Kamp G J; Hilgers J
Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992;13(1-2):18-26.
1992: Nijman H W; Burger C W; Baak J P; Schats R; Vermorken J B; Kenemans P
Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases.
European journal of cancer (Oxford, England : 1990) 1992;28A(12):1971-3.
1991: Massuger L F; Boerman O C; Corstens F H; Verheijen R H; Claessens R A; Poels L G; van den Broek W J; Kenemans P
Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice.
Anticancer research 1991;11(6):2051-7.
1991: Massuger L F; Kenemans P; Claessens R A; Verheijen R H; Corstens F H
Detection and localization of ovarian cancer with radiolabeled monoclonal antibodies.
European journal of obstetrics, gynecology, and reproductive biology 1991;41(1):47-63.
1991: Massuger L F; Claessens R A; Kenemans P; Verheijen R H; Boerman O C; Meeuwis A P; Schijf C P; Buijs W C; Hanselaar T G; Corstens F H
Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancer.
Nuclear medicine communications 1991;12(7):593-609.
1991: Van Den Brule A J; Walboomers J M; Du Maine M; Kenemans P; Meijer C J
Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia.
International journal of cancer. Journal international du cancer 1991;48(3):404-8.
1991: Buist M R; Roos J C; Vermorken J B; Golding R P; Burger C W; Kenemans P
[The diagnostic value of immunoscintigraphy using the monoclonal antibody OV-TL3 in patients with ovarian carcinoma]
Nederlands tijdschrift voor geneeskunde 1991;135(4):126-30.
1991: Yedema K A; Kenemans P; Wobbes T; van Kamp G J; de Bruijn H W; Thomas C M; Massuger L F; Schijf C P; Bon G G; Vermorken J B
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
International journal of cancer. Journal international du cancer 1991;47(2):170-9.
1991: Boerman O C; van Niekerk C C; Makkink K; Hanselaar T G; Kenemans P; Poels L G
Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1991;10(1):15-25.
1991: Massuger L F; Claessens R A; Pak K Y; Boerman O C; Daddona P E; Koenders E B; Kenemans P; Corstens F H
Tissue distribution of 99mTc, 111In and 123I-OV-TL 3 Fab' in ovarian carcinoma bearing nude mice.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(1):77-83.
1990: Massuger L F; Kenemans P; Claessens R A; Verheijen R H; Schijf C P; Strijk S P; Poels L G; van Hoesel R G; Corstens F H
Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(11):1802-10.
1990: Boerman O; Massuger L; Makkink K; Thomas C; Kenemans P; Poels L
Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
Anticancer research 1990;10(5A):1289-95.
1990: Massuger L; Claessens R; Kenemans P; Hanselaar T; Corstens F
Nonantigen-specific tissue localization of monoclonal antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(8):1438.
1990: Boerman O C; Segers M F; Poels L G; Kenemans P; Thomas C M
Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay.
Clinical chemistry 1990;36(6):888-91.
1990: Helmerhorst T J; Franke H R; Risse E K; Heeregrave-Bechthold M; Kenemans P; Stolk J G
Endocervical curettage by Vabra aspiration as part of colposcopic evaluation.
Gynecologic oncology 1990;36(3):312-6.
1990: Boerman O C; Makkink W K; Thomas C M; Hanselaar A G; Yedema C A; Kenemans P; Poels L G
Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
European journal of cancer (Oxford, England : 1990) 1990;26(2):117-27.
1990: Helmerhorst T J; van der Vaart C H; Dijkhuizen G H; Calame J J; Kenemans P; Stolk J G
CO2-laser therapy in patients with vulvar intraepithelial neoplasia.
European journal of obstetrics, gynecology, and reproductive biology 1990;34(1-2):149-55.
1989: Helmerhorst T J; Wijnen H J; Kenemans P; Tjioe G S; Dijkhuizen H H; Calame J J; Stolk H G
Colposcopic findings and intraepithelial neoplasia in diethylstilbestrol-exposed offspring. The Dutch experience.
American journal of obstetrics and gynecology 1989;161(5):1191-4.
1989: Boerman O; Makkink K; Massuger L; Thomas C; Kenemans P; Hanselaar T; Poels L
Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
Anticancer research 1989;9(3):551-8.
1989: Meijer C J; Calame J J; de Windt E J; Risse E K; Bleker O P; Kenemans P; Quint W G; Meddens M J
Prevalence of Chlamydia trachomatis infection in a population of asymptomatic women in a screening program for cervical cancer.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1989;8(2):127-30.
1988: Kenemans P; Yedema C A; Hilgers J H; Massuger L F; Verheijen R H; Thomas C M; Poels L G
Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens.
European journal of obstetrics, gynecology, and reproductive biology 1988;29(3):207-18.
1988: Henzen-Logmans S C; Schipper N W; Poels L G; Stolk K; Kenemans P; Meyer C J
Use of statistical evaluation of antigen profiles in differential diagnosis between colonic and ovarian adenocarcinomas.
Journal of clinical pathology 1988;41(6):644-9.
1988: Kühnel R; Rao B R; Poels L G; Delemarre J F; Kenemans P; Stolk J G
Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
Anticancer research 1988;8(2):281-6.
1988: Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P
Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1988;3():61-7.
1987: Boerman O C; Thomas C M; Segers M F; Kenemans P; Lövgren T; Zurawski V R; Haisma H J; Poels L G
Time-resolved immunofluorometric assay for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
Clinical chemistry 1987;33(12):2191-4.
1983: Franke H R; Risse E K; Kenemans P; Vooijs G P; Stolk J G
Epidemiologic features of hydatidiform mole in the Netherlands.
Obstetrics and gynecology 1983;62(5):613-6.
1983: Franke H R; Risse E K; Kenemans P; Houx P C; Stolk J G; Vooijs G P
Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Obstetrics and gynecology 1983;62(4):467-73.

Sign-in to see more